Agios Pharmaceuticals, Inc.
$27.07
▲
2.95%
2026-04-21 05:08:01
www.agios.com
NMS: AGIO
Explore Agios Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.54 B
Current Price
$27.07
52W High / Low
$46 / $22.24
Stock P/E
—
Book Value
$20.41
Dividend Yield
—
ROCE
-38.86%
ROE
-30.2%
Face Value
—
EPS
$-7.12
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
539
Beta
0.79
Debt / Equity
3.37
Current Ratio
11.46
Quick Ratio
11.06
Forward P/E
-6.73
Price / Sales
35.7
Enterprise Value
$1.11 B
EV / EBITDA
-2.39
EV / Revenue
20.63
Rating
Buy
Target Price
$43.75
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Catalyst Pharmaceuticals, Inc. | $26.07 | 14.85 | $3.18 B | — | 26.94% | 25.49% | $26.58 / $19.05 | $7.79 |
| 2. | Contineum Therapeutics, Inc. | $13.47 | — | $524.38 M | — | -25.5% | -26.13% | $16.33 / $3.35 | $6.99 |
| 3. | Madrigal Pharmaceuticals, Inc. | $535 | — | $12.26 B | — | -31.61% | -42.49% | $615 / $265 | $26.39 |
| 4. | Connect Biopharma Holdings Limited | $2.68 | — | $158.82 M | — | -24.19% | -82.72% | $3.82 / $0.65 | $0.74 |
| 5. | Xeris Biopharma Holdings, Inc. | $6.25 | 1,885.02 | $1.04 B | — | 9.09% | -6.96% | $10.08 / $3.95 | $0.08 |
| 6. | Syndax Pharmaceuticals, Inc. | $23.78 | — | $2.1 B | — | -66.67% | -1.62% | $25.59 / $8.58 | $0.74 |
| 7. | MindWalk Holdings Corp. | $1.27 | — | $59.32 M | — | -34.42% | -58.82% | $3.25 / $0.4 | $0.23 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 19.97 M | 12.88 M | 12.46 M | 8.73 M | 10.73 M | — |
| Operating Profit | -121.58 M | -116.87 M | -127.06 M | -106.63 M | -125.04 M | — |
| Net Profit | -108.04 M | -103.43 M | -112.02 M | -89.29 M | -96.52 M | — |
| EPS in Rs | -1.84 | -1.77 | -1.91 | -1.52 | -1.65 | 16.22 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 54.03 M | 36.5 M | 26.82 M | 14.24 M |
| Operating Profit | -472.13 M | -425.74 M | -391.49 M | -389.05 M |
| Net Profit | -412.78 M | 673.73 M | -352.09 M | -231.8 M |
| EPS in Rs | -7.04 | 11.5 | -6.01 | -3.96 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.3 B | 1.66 B | 937.12 M | 1.24 B |
| Total Liabilities | 104.11 M | 122.24 M | 126.1 M | 137.9 M |
| Equity | 1.19 B | 1.54 B | 811.02 M | 1.1 B |
| Current Assets | 942.05 M | 965.6 M | 833.84 M | 832.77 M |
| Current Liabilities | 82.21 M | 81.16 M | 67.95 M | 62.63 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -372.98 M | -389.84 M | -296.06 M | -309.48 M |
| Investing CF | 377.18 M | 363.44 M | 239.57 M | 243.26 M |
| Financing CF | 8.68 M | 14.44 M | 5.43 M | 2.35 M |
| Free CF | -387.29 M | -391.53 M | -314.56 M | -314.36 M |
| Capex | -14.32 M | -1.69 M | -18.5 M | -4.88 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 36.07% | 88.36% | — | — |
| Earnings Growth % | 291.35% | -51.89% | — | — |
| Profit Margin % | 1845.92% | -1312.63% | -1627.82% | — |
| Operating Margin % | -1166.47% | -1459.52% | -2732.07% | — |
| Gross Margin % | 88.59% | 89.26% | 88.03% | — |
| EBITDA Margin % | -1150.98% | -1434.83% | -2671.93% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.